Actively Recruiting

Phase 2
Phase 3
Age: 40Years - 80Years
All Genders
NCT06125327

SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Led by Guangzhou JOYO Pharma Co., Ltd · Updated on 2024-11-19

210

Participants Needed

1

Research Sites

238 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Evaluating Sufenidone (SC1011) in IPF patients for efficacy and safety. Includes screening, treatment, and follow-up, with FVC decline and health checks.

CONDITIONS

Official Title

SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Who Can Participate

Age: 40Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to understand and sign informed consent
  • Diagnosed with Idiopathic Pulmonary Fibrosis (IPF) less than 5 years before enrollment
  • Diagnosis confirmed by HRCT pattern and, if available, surgical lung biopsy assessed by central reviewers
  • Diffusing capacity for carbon monoxide (Dlco), corrected for hemoglobin, between 30% and 90% of predicted normal
  • Forced vital capacity (FVC) 50% or more of predicted normal
Not Eligible

You will not qualify if you...

  • Forced expiratory volume in one second (FEV1)/FVC ratio less than 0.7 after bronchodilator at screening
  • Expected lung transplant within 1 year or on lung transplant waiting list (for US sites) at randomization
  • Known cause of interstitial lung disease other than IPF
  • History of asthma or chronic obstructive pulmonary disease
  • Active infection at screening
  • Current use of IPF treatments including investigational therapy, immunosuppressants, or cytokine modulating agents
  • History of unstable or worsening cardiac or pulmonary disease (other than IPF) within past 6 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100703

Actively Recruiting

Loading map...

Research Team

Z

zuojun xu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here